Title |
Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice
|
---|---|
Published in |
Biomarker Research, February 2018
|
DOI | 10.1186/s40364-018-0120-4 |
Pubmed ID | |
Authors |
Vicki Xie, Daochen Tong, Craig T. Wallington-Beddoe, Ken F. Bradstock, Linda J. Bendall |
Abstract |
Sphingosine kinase (SphK) 2 has been implicated in the development of a range of cancers and inhibitors of this enzyme are currently in clinical trial. We have previously demonstrated a role for SphK2 in the development of acute lymphoblastic leukemia (ALL). In this and our previous study we use mouse models: in the previous study the disease was driven by the proto-oncogene BCR/ABL1, while in this study cancer risk was elevated by deletion of the tumor suppressor ARF. Mice lacking ARF and SphK2 had a significantly reduced incidence of ALL compared mice with wild type SphK2. These results show that the role of SphK2 in ALL development is not limited to BCR/ABL1 driven disease extending the potential use of inhibitors of this enzyme to ALL patients whose disease have driver mutations other than BCR/ABL1. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 7 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 1 | 14% |
Professor > Associate Professor | 1 | 14% |
Researcher | 1 | 14% |
Lecturer | 1 | 14% |
Unknown | 3 | 43% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 2 | 29% |
Biochemistry, Genetics and Molecular Biology | 1 | 14% |
Unknown | 4 | 57% |